LEGN LEGEND BIOTECH CORP

Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results

Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results

SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 13, 2025, to review first-quarter 2025 results.

During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter.

Investors and other interested parties may join the live audio webcast of the call via this .

A replay of the webcast and earnings news release will be available through the section of Legend Biotech’s website under the section approximately two hours after the call concludes.

ABOUT LEGEND BIOTECH

With over 2,500 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at , and follow us on and .

INVESTOR CONTACT:

Jessie Yeung

Tel: (732) 956-8271

PRESS CONTACT:

Mary Ann Ondish

Tel: (914) 552-4625





EN
29/04/2025

Underlying

LEGNLEGEND BIOTECH CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LEGEND BIOTECH CORP

 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKT...

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ≥5 years CARTITUDE-4 subgroup analyses featured in a poster presentation highlight consistent, durable progression-free and overall survival benefit vs. standard therapies across cytogenetic risk groups as early as second-line therapyPromising early results from ongoing Phase...

June 3, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Devel...

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single CARVYKTI® infusion New data at ASCO from the CARTITUDE-4 study to showcase improved progression-free survival and overall survival with CARVYKTI® versus standard of care (SOC) in key subgroups Preliminary results from ongoing Phase 1 dose-escalation studies of LB2102 in lung cancers and LB1908 in gastroes...

May 22, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech to Host Investor Event During the 2025 American Society...

Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00 p.m. CT (7:00 p.m. ET) during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinici...

May 19, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech Reports First Quarter 2025 Results and Recent Highlight...

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 millionOver 6,000 patients treated to dateInitiated CARVYKTI® clinical production at the Tech Lane facilityReceived positive CHMP opinion to add statistically significant improvement in overall survival from CARTITUDE-4 study to CARVYKTI® labelAustralia’s TGA approved CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.0 billion, as of March 31, 2025, which Legend Biot...

May 13, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech to Host Investor Conference Call on First Quarter 2025 ...

Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 13, 2025, to review first-quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this . A replay of the webcast and...

April 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch